What is the latest market price of a box of Pimitespib?

Pimitespib (trade name: Jeselhy®) is an oral HSP90 inhibitor, mainly used to treat patients with gastrointestinal stromal tumors (GIST) that have progressed after chemotherapy. The drug was developed by Japan's Taiho Pharmaceutical Company (Taiho Pharmaceutical) and was approved for marketing by the Japanese Ministry of Health, Labor and Welfare in June 2022. Currently, pimetibib has not been approved for marketing in mainland China, so domestic patients cannot purchase the drug through formal channels.

Currently, only the Japanese originator version of pimotebi is available in the global market. The Japanese version of the original drug produced by Japan's Dapeng Pharmaceutical Company is currently the only pimetibib on the market. Its price is relatively high, with a box price of about more than 10,000 yuan. This price is still a large financial burden for some patient families with average financial conditions, especially when long-term treatment is required.

It is worth noting that as of now, there are no generic drugs of pimetibib on the global market. This means that patients can only choose the Japanese original version when purchasing, and cannot enjoy the price advantage brought by generic drugs. This singleness in drug selection also limits patients’ medication accessibility to a certain extent. Therefore, if the patient really needs medication, he should try to purchase the medication through qualified overseas medical services or channels and cooperate with the doctor for standardized treatment.

In general, although pimetibib is an emerging targeted drug, it is difficult to obtain due to the fact that it has not yet been launched in my country and the high price of the original research. If patients plan to use this drug, they should conduct KRAS G12C mutation-related examinations in advance and evaluate the necessity of medication under the guidance of a professional doctor. At the same time, attention should also be paid to the approval status of this drug in China so that treatment resources can be more conveniently and reasonably obtained in the future.

Reference materials:https://www.mt-pharma.co.jp/e/company/rd/pipe/